GlobeNewswire Inc | Sep 21, 2021 08:00AM EDT

September 21, 2021

AUSTIN, Texas, Sept. 21, 2021 (GLOBE NEWSWIRE) -- Aspira Womens Health, Inc. (Nasdaq: AWH), a bioanalytical-based womens health company, today announced that it will present at the Cantor Fitzgerald Virtual Global Healthcare Conference on Wednesday, September 29th, 2021.

Details for the presentation are below:

Date: September 29^th, 2021Time: 4:40pm ETWebcast https://wsw.com/webcast/cantor12/awh/1906240

Management will also be available for virtual 1x1 meetings. To request a meeting, please contact corporateaccess@cantor.com.

About ASPIRA Womens Health Inc.Aspira Womens Health Inc. (formerly known as Vermillion, Inc., Nasdaq: VRML) is transforming womens health with the discovery, development, and commercialization of innovative testing options and bio-analytical solutions that help physicians assess risk, optimize patient management, and improve gynecologic health outcomes for women. Aspira Womens Health is particularly focused on closing the ethnic disparity gap in ovarian cancer risk assessment and developing solutions for pelvic diseases such as pelvic mass risk assessment and endometriosis. OVA1 plus combines our FDA-cleared products, OVA1 and OVERA, to detect risk of ovarian malignancy in women with adnexal masses. ASPIRA GenetiXSM testing offers both targeted and comprehensive genetic testing options with a gynecologic focus. With over 10 years of expertise in ovarian cancer risk assessment, Aspira Womens Health has expertise in cutting-edge research to inform our next generation of products. Our focus is on delivering products that allow healthcare providers to stratify risk, facilitate early detection and optimize treatment plans. The next generation of products in development are OVAWatchand EndoCheck. Visit our website for more information at www.aspirawh.com.

Investor Relations Contact:Ashley R. RobinsonLifeSci Advisors, LLCTel: 617-430-7577arr@lifesciadvisors.com